scispace - formally typeset
H

Hugues Legendre

Researcher at Institut Jules Bordet

Publications -  13
Citations -  657

Hugues Legendre is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 8, co-authored 13 publications receiving 639 citations.

Papers
More filters
Journal ArticleDOI

Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting

TL;DR: The current study analyzed the prognostic values contributed by galectin‐1, galECTin‐3, galect in‐4, and galectIn‐4 in cases of colon carcinoma to find out whether these values are related to prognostic value or not.
Journal ArticleDOI

Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration

TL;DR: Their expression significantly increased with the degree of dysplasia, suggesting that gal‐1 and gal‐3 and their binding sites are related to malignant progression, while gal‐8 has been associated with suppressor activity.
Journal ArticleDOI

Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor

TL;DR: The present study deals with the quantitative determination of immunohistochemical expression of galectin-8 in normal, benign, and malignant human colon tissue samples and in four human colon cancer models maintained both in vitro as permanent cell lines and in vivo as nude mice xenografts.
Journal ArticleDOI

Prognostic Values of Galectin-3 and the Macrophage Migration Inhibitory Factor (MIF) in Human Colorectal Cancers

TL;DR: MIF and galectin-3 expression levels in colorectal tumors are related to their levels of biological aggressiveness and could be used to identify patients at risk, for whom more aggressive adjuvant therapy seems to be indicated.
Journal ArticleDOI

Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction

TL;DR: Palliative surgery can, in a certain number of cases, improve the quality of life of patients, but it has not been possible for us to demonstrate prognostic factors which would allow the selection of patients who could benefit the most from such surgery.